.png)
When your mission is as ambitious as ending the diagnostic odyssey for families with rare diseases, going it alone isn’t an option. At TMA Precision Health, collaboration isn’t just a strategy, it’s the foundation of everything the organization has built over the last six years.
As CEO and Founder, Josh Resnikoff shared in a recent episode of The Sunstone Health Podcast, every breakthrough, connection, and opportunity in the rare disease space begins with one thing: people.
“Almost everything I have achieved has come from the network I’ve been able to build over time: people who do good work and who care deeply about this mission.”
— Josh Resnikoff
In traditional industries, partnerships often start with contracts and metrics. But in healthcare, there’s a famous saying that “health moves at the speed of trust.” It’s especially true in rare diseases, where alignment comes first.
One in every nine people faces a genetic condition, a statistic that underscores just how broad and interconnected this challenge is. Addressing it requires collaboration across every corner of the healthcare ecosystem.
Helping a clinician get answers for a patient
Supporting a researcher uncovering new pathways in genomics
Guiding families through uncertainty
Empowering payers and policymakers to rethink what’s possible
Those who partner with TMA understand that value isn’t just financial, it’s human.
“I really believe that you get back more than you give. And so we try to give as much as possible.”
Josh has spent years in conference halls and hospital corridors, cultivating trust handshake by handshake. Some networks are built quickly. Others require years of persistence before they unlock meaningful progress.
TMA is now experiencing that long-awaited momentum: keynote invitations at major conferences, large-scale deployments with health organizations, and growing visibility across the global rare disease community.
But this progress didn’t come from luck or a viral moment, it came from steadfast relationship-building.
“It only takes 10 years to become an overnight success.”
Josh has seen both sides, a startup that went viral almost instantly, and now a company requiring years of dedication to build credibility in one of the most complex areas of medicine.
“It’s not ‘fake it till you make it.’
It’s ‘learn it till you earn it.’”
That mindset has attracted some of the brightest minds from institutions like Mass General, Harvard, and major global innovators who believe in TMA’s vision and want to help accelerate change.
Every connection matters. A mother seeking answers. A researcher with breakthrough data. A policymaker eager to improve access. A nonprofit ready to expand advocacy efforts.
These contributions collectively elevate the rare disease ecosystem and, in turn, help TMA reach more families who desperately need clarity.
“There’s no utility in gatekeeping relationships that can advance the entire field.”
When lives are at stake, collaboration isn’t optional, it’s the only moral choice.
As TMA prepares for some of its largest events and initiatives yet, including Epilepsy Awareness Day and expanding work across global health plans, partnerships remain the strongest indicator of what's ahead.
The more people united in this mission, the faster we change healthcare for rare disease families everywhere.
Because when we connect, we create impact.
When we collaborate, we accelerate progress.
And together, we can end the diagnostic odyssey.